Peripheral T Cell Lymphoma: Clinical Trials

7 trials for Peripheral T Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting, 1 completed, 1 not yet recruiting. 7 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1
Phase 22Not yet recruiting 1, Recruiting 1

Follow Peripheral T Cell Lymphoma: new trials by email Literature Review of Peripheral T Cell Lymphoma trials Research Report on Peripheral T Cell Lymphoma

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
golidocitinib, Placebo - Peripheral T Cell Lymphoma
Phase 3RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine682026-02-152026-02-24
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Cidabenamine, Azacitidine - Peripheral T Cell Lymphoma
Phase 2 / Phase 3RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine402026-02-012026-02-05
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
Linperlisib - Peripheral T Cell Lymphoma
Phase 2 / Phase 3Not yet recruitingShanghai YingLi Pharmaceutical Co. Ltd.6062024-09-102024-08-12
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma
Phase 3Active not recruitingAcrotech Biopharma Inc.5042023-10-042026-10-15
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
Mitoxantrone Hydrochloride Liposome Injection, Chidamide - Peripheral T Cell Lymphoma
Phase 3Active not recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.1932021-04-132025-05-31
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
chidamide, cyclophosphamide, liposomal doxorubicin - Peripheral T Cell Lymphoma
Phase 3UnknownNanfang Hospital, Southern Medical University1742017-02-012017-01-18
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma
CHOP21, VIP/ABVD, Radiotherapy consolidation - Peripheral T Cell Lymphoma
Phase 3CompletedUniversity Hospital, Grenoble951995-01-012009-09-09

Narrower conditions

Lymphoma, T-Cell, Peripheral (7)

Broader conditions

Hemic and Lymphatic Diseases (7)  ·  Immune System Diseases (7)  ·  Immunoproliferative Disorders (7)  ·  Lymphatic Diseases (7)  ·  Lymphoma (7)  ·  Lymphoma, Non-Hodgkin (7)  ·  Lymphoma, T-Cell (7)  ·  Lymphoproliferative Disorders (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)

Interventions

Cyclophosphamide (2)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2)  ·  Prednisone (2)  ·  Vincristine (2)  ·  10-propargyl-10-deazaaminopterin (1)  ·  Azacitidine (1)  ·  CHOP protocol (1)  ·  Doxorubicin (1)  ·  belinostat (1)  ·  liposomal doxorubicin (1)

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2)  ·  Acrotech Biopharma Inc. (1)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)  ·  Nanfang Hospital, Southern Medical University (1)  ·  Shanghai YingLi Pharmaceutical Co. Ltd. (1)  ·  University Hospital, Grenoble (1)

Countries

China (4)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Poland (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)  ·  United States (1)

Top investigators

Ru Feng, M.D. (1)  ·  Uma Srinivas Atmuri, MPharm, MS (1)